Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
This study has been completed.
Study NCT00430846   Information provided by Seattle Genetics, Inc.

First Received on February 1, 2007.   Last Updated on June 6, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, Non-Hodgkin
Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Additional conditions recognized in this trial
Hematologic Neoplasms
Hodgkin Disease
Lymphoma
Lymphoma, Large B-Cell, Diffuse
More general conditions related to this trial
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, B-Cell
Lymphoma, T-Cell
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Interventions listed in this trial
SGN-35
Sponsors listed in this trial
Seattle Genetics, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services